	US 11,752,197 B2
	Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
Julie Horowitz, Tarrytown, NY (US); Aris Baras, Tarrytown, NY (US); and Manuel Allen Revez Ferreira, Tarrytown, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Aug. 11, 2020, as Appl. No. 16/990,744.
Claims priority of provisional application 62/885,402, filed on Aug. 12, 2019.
Prior Publication US 2021/0046157 A1, Feb. 18, 2021
Int. Cl. A61K 38/18 (2006.01); A61K 38/17 (2006.01); A61P 1/00 (2006.01); A61K 31/12 (2006.01); A61K 31/4741 (2006.01); A61K 38/48 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01); G01N 33/48 (2006.01); G01N 33/53 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/68 (2018.01)

CPC A61K 38/18 (2013.01) [A61K 31/12 (2013.01); A61K 31/4741 (2013.01); A61K 38/177 (2013.01); A61K 38/1709 (2013.01); A61K 38/1796 (2013.01); A61K 38/482 (2013.01); A61K 38/4846 (2013.01); A61K 38/4853 (2013.01); A61P 1/00 (2018.01); C07K 16/22 (2013.01); C07K 16/2863 (2013.01); C12Q 1/6883 (2013.01); G01N 33/6893 (2013.01); C12Q 1/68 (2013.01); C12Q 1/6827 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); G01N 33/48 (2013.01); G01N 33/53 (2013.01); G01N 2333/475 (2013.01); G01N 2333/71 (2013.01); G01N 2800/065 (2013.01)]

23 Claims

1. A method of treating a patient having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC), the method comprising administering to the patient an agonist of the Macrophage Stimulating 1 (MST1)/Macrophage Stimulating 1 Receptor (MST1R) pathway, thereby treating the patient, wherein the agonist is an MST1 protein.